Skip to main content
TipRanks
Go Ultimate75% OFF

Interpace Diagnostics Group (IDXG) Stock Statistics & Valuation Metrics

413 Followers

Total Valuation

Interpace Diagnostics Group has a market cap or net worth of $35.41M. The enterprise value is $43.46M.

Market Cap
$35.41M
Enterprise Value
$43.46M

Share Statistics

Interpace Diagnostics Group has 5,901,964 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
5,901,964
Owned by Insiders
90.61%
Owned by Institutions
―

Financial Efficiency

Interpace Diagnostics Group’s return on equity (ROE) is 1.10 and return on invested capital (ROIC) is 14.00%.

Return on Equity (ROE)
1.10
Return on Assets (ROA)
0.73
Return on Invested Capital (ROIC)
14.00%
Return on Capital Employed (ROCE)
0.14
Revenue Per Employee
379.69K
Profits Per Employee
240.93K
Employee Count
102
Asset Turnover
1.14
Inventory Turnover
13.10

Valuation Ratios

The current PE Ratio of Interpace Diagnostics Group is 0.23. Interpace Diagnostics Group’s PEG ratio is 0.00.

PE Ratio
0.23
PS Ratio
0.94
PB Ratio
1.39
Price to FCF
15.51
Price to Operating Cash Flow
13.59
PEG Ratio
0.00

Income Statement

In the last 12 months, Interpace Diagnostics Group had revenue of 38.73M and earned 24.57M in profits. Earnings per share was 27.75.

Revenue
38.73M
Gross Profit
24.13M
Operating Income
4.08M
Pretax Income
3.77M
Net Income
24.57M
EBITDA
4.76M
Earnings Per Share (EPS)
27.75

Cash Flow

In the last 12 months, operating cash flow was 4.46M and capital expenditures -353,000, giving a free cash flow of 4.10M billion.

Operating Cash Flow
4.46M
Free Cash Flow
4.10M
Free Cash Flow per Share
0.40

Dividends & Yields

Interpace Diagnostics Group pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
6.45%
Earnings Yield
64.05%

Stock Price Statistics

Beta
1.36
52-Week Price Change
21.21%
50-Day Moving Average
6.12
200-Day Moving Average
8.07
Relative Strength Index (RSI)
49.03
Average Volume (3m)
2,741

Important Dates

Interpace Diagnostics Group upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 16, 2026
Next Earnings Date
Mar 31, 2027
Ex-Dividend Date
―

Financial Position

Interpace Diagnostics Group as a current ratio of 1.94, with Debt / Equity ratio of 5.29%

Current Ratio
1.94
Quick Ratio
1.72
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.28
Interest Coverage Ratio
24.31

Taxes

In the past 12 months, Interpace Diagnostics Group has paid -21.21M in taxes.

Income Tax
-21.21M
Effective Tax Rate
-5.62

Enterprise Valuation

Interpace Diagnostics Group EV to EBITDA ratio is 24.89, with an EV/FCF ratio of 14.40.

EV to Sales
0.87
EV to EBITDA
24.89
EV to Free Cash Flow
14.40
EV to Operating Cash Flow
13.05

Balance Sheet

Interpace Diagnostics Group has $2.69M in cash and marketable securities with $974.00K in debt, giving a net cash position of $1.71M billion.

Cash & Marketable Securities
$2.69M
Total Debt
$974.00K
Net Cash
$1.71M
Net Cash Per Share
$0.29
Tangible Book Value Per Share
$4.20

Margins

Gross margin is 65.63%, with operating margin of 1.65%, and net profit margin of 58.07%.

Gross Margin
65.63%
Operating Margin
1.65%
Pretax Margin
1.34%
Net Profit Margin
58.07%
EBITDA Margin
3.50%
EBIT Margin
8.02%

Analyst Forecast

The average price target for Interpace Diagnostics Group is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-20.48%
EPS Growth Forecast
537.47%

Scores

Smart Score
―
AI Score
62